Opinion|Videos|April 25, 2025
Case Discussion: Integrating PSMA PET for Focal Boost Optimization
Panelists discuss how PSMA PET imaging identified a region of high tracer uptake, guiding medical professionals to implement a focal radiation boost. This approach improved treatment precision and targeting of aggressive areas, highlighting the potential for personalized, effective therapies.
Advertisement
Video content above is prompted by the following:
- Please share an example where you implemented a focal boost based on prostate-specific membrane antigen (PSMA) uptake intensity.
- What findings did PSMA PET imaging provide, and how did this help guide your decisions?
- Briefly comment on this case and discuss implications for the practice setting.
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer.
Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5